# AUGTYRO (repotrectinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/repotrectinib

> The FDA approved AUGTYRO (repotrectinib), sponsored by BRISTOL MYERS SQUIBB CO (BMY), on November 15, 2023 for to treat ROS1-positive non-small cell lung cancer.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is AUGTYRO (repotrectinib) FDA approved?

Yes. The FDA approved AUGTYRO (repotrectinib), sponsored by BRISTOL MYERS SQUIBB CO (BMY), on November 15, 2023 for to treat ROS1-positive non-small cell lung cancer. FDA novel drug approvals: "Augtyro | repotrectinib | 11/15/2023 | To treat ROS1-positive non-small cell lung cancerDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/repotrectinib)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/repotrectinib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | AUGTYRO (repotrectinib) |
| Codes | BMS-986472 |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | To treat ROS1-positive non-small cell lung cancer, [Carcinoma, Non-Small-Cell Lung](https://sec-api.dev/indications/carcinoma-non-small-cell-lung) |
| Modality | small_molecule |
| FDA designations | priority review |

## Timeline

### November 15, 2023: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat ROS1-positive non-small cell lung cancer.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Augtyro | repotrectinib | 11/15/2023 | To treat ROS1-positive non-small cell lung cancerDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023
- openFDA Drugs@FDA: "NDA218213 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20231115, review_priority PRIORITY; sponsor_name BRISTOL; product AUGTYRO (REPOTRECTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218213%22

### June 13, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA218213 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20240613, review_priority PRIORITY; sponsor_name BRISTOL; product AUGTYRO (REPOTRECTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218213%22

### 1H 2025: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2025-02-27, last confirmed 2025-02-27.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-008406): "Zai Lab plans to submit a supplemental NDA to the NMPA in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1704292/000162828025008406/zlab-20250227x8kex991.htm

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06140836 (A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-16 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06140836

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06140836 (A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-16 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06140836

## Same indication

- [6-thio-2'-deoxyguanosine](https://sec-api.dev/pdufa/6-thio-2-deoxyguanosine) (MAIA)
- [Krazati (adagrasib)](https://sec-api.dev/pdufa/adagrasib) (BMY)
- [Disitamab vedotin](https://sec-api.dev/pdufa/disitamab-vedotin) (PFE)
- [JNJ-90301900](https://sec-api.dev/pdufa/jnj-90301900) (JNJ)
- [Navlimetostat](https://sec-api.dev/pdufa/navlimetostat) (BMY)
- [Olomorasib](https://sec-api.dev/pdufa/olomorasib) (LLY)
- [Pembrolizumab/vibostolimab](https://sec-api.dev/pdufa/pembrolizumab-vibostolimab) (MRK)
- [Alimta (pemetrexed)](https://sec-api.dev/pdufa/pemetrexed) (LLY)
- [Retevmo (selpercatinib)](https://sec-api.dev/pdufa/selpercatinib) (LLY)
- [Sigvotatug vedotin](https://sec-api.dev/pdufa/sigvotatug-vedotin) (PFE)

Calendar months: [February 2027](https://sec-api.dev/fda-calendar/2027-02)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/repotrectinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AUGTYRO (repotrectinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/repotrectinib

```bibtex
@misc{secapidev_pdufa_repotrectinib_20261116,
  title        = {AUGTYRO (repotrectinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/repotrectinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_repotrectinib_20261116","title":"AUGTYRO (repotrectinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/repotrectinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
